RxDoctor Payments Data

Jennifer Margopulos Kelenske, PA

Physician Assistant · Asheville, NCNPI 1548339930

Payments from drug & device makers

$4,812in general payments, 2019–2025

Across 89 payments — averaging $54.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • AbbVie$602
  • Intercept Pharmaceuticals, Inc.$279
  • Madrigal Pharmaceuticals$220
  • Ironwood Pharmaceuticals, Inc$184
  • Enterra Medical, Inc.$145
  • plus $706 from 12 others

What the payments were for

  • Speaking & faculty fees$1303%
  • Travel & lodging$2,29148%
  • Food & beverage$2,31548%
  • Education$752%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,812 in reported general payments places this provider in the 90th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$55,778
Medicare patients
320
Services billed
729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid26$250,108
XifaxanRifaximin60$192,422
LinzessLinaclotide77$61,622
MotegrityPrucalopride Succinate41$25,706
Ursodiol62$11,030
Mesalamine19$10,789
Dexlansoprazole DrDexlansoprazole30$6,003
Balsalazide Disodium19$4,895
Lubiprostone37$4,439
MovantikNaloxegol Oxalate11$4,190
Colestipol Hcl32$3,775
Azathioprine24$3,364
Esomeprazole Magnesium64$2,748
Omeprazole200$1,997
Pantoprazole Sodium75$1,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$279$250,10826 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$39$192,42260 claims
AbbVieLinzess$602$61,62277 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$85$25,70641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →